CRISPR Therapeutics AG Target Price

See CRISPR Therapeutics AG's analyst price targets ($68) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$52.97

Average Target Price

$67.83

28.1% upside

6 analysts in the last 4 months

High: $80 | Low: $55

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-06	Goldman Sachs	$55	3.8% upside
2026-07-08	H.C. WainwrightMitchell Kapoor	$80	51% upside
2026-06-12	UBS	$80	51% upside
2026-06-11	Morgan StanleyMaxwell Skor	$60	13.3% upside
2026-05-13	Bernstein	$56	5.7% upside
2026-05-11	Evercore ISI	$76	43.5% upside
2026-02-17	Morgan Stanley	$33	37.7% downside
2026-02-14	Chardan CapitalGeulah Livshits	$76	43.5% upside
2026-02-13	Needham	$82	54.8% upside
2026-02-13	Evercore ISI	$74	39.7% upside
2025-11-26	Chardan Capital	$74	39.7% upside
2025-11-11	RBC CapitalLuca Issi	$50	5.6% downside
2025-10-13	Wells FargoYanan Zhu	$75	41.6% upside
2025-02-03	H.C. WainwrightMitchell Kapoor	$65	22.7% upside
2024-11-06	OppenheimerJay Olson	$95	79.3% upside
2024-11-05	Leerink PartnersRick Bienkowski	$67	26.5% upside
2024-08-12	Truist FinancialJoon Lee	$100	88.8% upside
2024-08-06	NeedhamGil Blum	$84	58.6% upside
2024-08-06	Stifel NicolausBenjamin Burnett	$59	11.4% upside
2024-08-06	RBC CapitalLuca Issi	$60	13.3% upside
2024-05-09	Robert W. BairdJack Allen	$52	1.8% downside
2022-11-23	Citigroup	$63	18.9% upside
2022-08-09	Chardan CapitalGeulah Livshits	$79.3	49.7% upside
2022-06-17	BMO CapitalKostas Biliouris	$98	85% upside
2022-04-28	Credit Suisse	$78	47.3% upside
2022-02-16	NeedhamGil Blum	$170	220.9% upside
2022-02-15	Leerink PartnersRick Bienkowski	$120	126.5% upside
2022-01-07	Wells FargoYanan Zhu	$105	98.2% upside
2021-11-04	OppenheimerJay Olson	$172	224.7% upside
2021-10-12	Piper SandlerEdward Tenthoff	$180	239.8% upside
2021-08-16	Canaccord GenuityArlinda Lee	$160	202.1% upside
2021-06-11	Roth CapitalAnthony Butler	$171	222.8% upside
2021-04-21	JefferiesMaury Raycroft	$172	224.7% upside

CRISPR Therapeutics AG (CRSP) FAQ

CRISPR Therapeutics AG posts a target price of $68. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $68 for CRSP means covering analysts, on average, see the stock 28.1% upside of $52.97 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CRSP's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; CRISPR Therapeutics AG's other metric pages and overview cover the third.

Judging CRISPR Therapeutics AG against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $68 here, then scan peer and history charts to see if the gap is persistent.